Navigation Links
Pharmacyclics Secures $5.0 Million in Debt Financing
Date:1/6/2009

from those in the forward-looking statements. Factors that could affect actual results include risks associated with unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the product development of our pipeline; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2008 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
2. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
3. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
4. Pharmacyclics Announces It Received Nasdaq Notification
5. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
6. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
7. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
8. Queens secures £25M for UKs cyber safety
9. Queens secures £25m for UKs cyber-safety
10. Northwest Secures US$1.65 Million Debt Financing
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015  Moerae Matrix Inc. announced ... clinical trial with MMI-0100, a first-in-class inhibitor of ... for pulmonary disorders characterized by inflammation and fibrosis.  ... Kingdom , is a double-blind, two-way cross-over ... safety and tolerability of MMI-0100 when given via ...
(Date:7/28/2015)... , July 28, 2015 ... company utilizing its proprietary plant-based rhCollagen technology for ... has been appointed Senior Director of Business Development, ... http://photos.prnewswire.com/prnh/20150728/246955 ) , Ms. ... marketing, regulatory and business strategy. Prior to joining ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... state of the Biophotonics industry.The report provides a basic overview of the industry ... provided for the international markets including development trends, competitive landscape analysis, and key ...
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® ... Monday. The venture will bring the world’s most efficient gas dissolution technology to ... and technologies to both the industrial and municipal markets. With offices located in ...
Breaking Biology Technology:Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 22015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3BlueInGreen Brings Water Treatment Technology to Florida 2
... IDM Pharma (Nasdaq:,IDMI) today announced that Jeffrey W. ... Medical Officer and Senior Vice President,of Research and Development. ... report to President and CEO Timothy P. Walbert. ... experience to,IDM Pharma and will lead the regulatory and ...
... NanoLogix, Inc. (OTC:,NNLX) is pleased to announce that ... Director of Intellectual Property. In addition, we wish ... the rapid detection of,Anthrax utilizing the NanoLogix BioNanoChannel(TM) ... experience as an intellectual property,counsel in a wide ...
... Drug Royalty LP 2 (DRC) announced,today the ... worldwide,royalty interest in PEG-INTRON for $92.5M. DRC will ... certain royalty recognition levels be met.,PEG-INTRON (peginterferon alpha-2b), ... is marketed worldwide by Schering-Plough Corporation (SGP). ...
Cached Biology Technology:IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 2IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 3IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 4IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 5NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection 2NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection 3Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN) 2
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... of American Societies for Experimental Biology (FASEB) is once ... together to prevent sequestration, the automatic across-the-board budget cuts ... 1st. "These automatic spending cuts will stop science advances ... jobs," said FASEB President, Judith S. Bond, PhD. , ...
... MRI and Honorary Lecturer in Cardiovascular Medicine at The University ... the only location in the UK where the trial is ... test manufacturer, to take part in the trial as he ... heart attacks. The other trial sites are in Australia, ...
... open for the Joint Annual Meeting of the American Dairy ... meeting will take place in Indianapolis, IN from July 8 ... feature 35 symposia on topics such as animal genetics, food ... workshops, including a hands-on media training workshop on July 12. ...
Cached Biology News:Manchester patients take part in pioneering heart attack blood test trial 2
Sheep Serum US Origin...
Human PDGF, CF...
Incomplete Adjuvant...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
Biology Products: